NRG肿瘤学RTOG 9006:超分割放疗联合卡莫司汀对比标准放疗联合卡莫司汀治疗恶性胶质瘤的III期随机试验
1990至1994年纳入712例新诊断恶性胶质瘤患者,随机接受超分割放疗(72.0 Gy/60次,每日两次)或标准放疗(60.0 Gy/30次,每日一次),均联合卡莫司汀80 mg/m2第1-3天每8周一次共1年。可分析694例(超分割组350例,标准组344例),两组急性和晚期治疗相关毒性无显著差异;超分割组与标准组中位总生存期11.3 vs 13.1个月(p=0.20),中位无进展生存期5.7 vs 6.9个月(p=0.18),多因素分析风险比1.16(p=0.0682),各组织学亚组均无显著差异。
要点
- 超分割放疗72.0 Gy/60次对比标准放疗60.0 Gy/30次,总生存期和无进展生存期均无显著差异
- 两组急性或晚期治疗相关毒性无显著差异
- 多因素分析风险比1.16(p=0.0682),各组织学亚组均无超分割放疗获益趋势
核心结论
- 该试验未发现超分割放疗至72.0 Gy在恶性胶质瘤任何亚组中有获益趋势或迹象。
研究设计与样本
- III期随机试验,1990至1994年入组712例新诊断恶性胶质瘤患者,可分析694例(超分割组350例,标准组344例)。
- 患者随机接受超分割放疗72.0 Gy/60次(每日两次)或标准放疗60.0 Gy/30次(每日一次),均联合卡莫司汀80 mg/m2第1-3天每8周一次共1年。
- 按年龄、KPS和組織學分层,主要终点为总生存期,次要终点包括无进展生存期和毒性。
主要发现
- 超分割组与标准组中位总生存期11.3 vs 13.1个月(p=0.20),中位无进展生存期5.7 vs 6.9个月(p=0.18),均无统计学显著差异。
- 多因素分析总生存期风险比1.16(p=0.0682),无统计学显著差异。
- 胶质母细胞瘤亚组中位总生存期10.3 vs 11.2个月(p=0.34),间变性星形细胞瘤69.8 vs 50.0个月(p=0.91),间变性少突胶质细胞瘤92.1 vs 66.5个月(p=0.33),均无显著差异。
- 两组急性或晚期治疗相关毒性无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
From 1990 to 1994, patients with newly diagnosed malignant gliomas were enrolled and randomized between hyperfractionated radiation (HFX) of 72.0 Gy in 60 fractions given twice daily and 60.0 Gy in 30 fractions given once daily. All patients received 80 mg/m2 of 1,3 bis(2 chloroethyl)-1 nitrosourea on days 1-3 q8 weeks for 1 year. Patients were stratified by age, KPS, and histology. The primary endpoint was overall survival (OS), with secondary endpoints including progression-free survival (PFS) and toxicity. Out of the 712 patients accrued, 694 (97.5%) were analyzable cases (350 HFX, 344 standard arm). There was no significant difference between the arms on overall acute or late treatment-related toxicity. No statistically significant effect for HFX, as compared to standard therapy, was found on either OS, with a median survival time (MST) of 11.3 versus 13.1 months (p = 0.20) or PFS, with a median PFS time of 5.7 versus 6.9 months (p = 0.18). The treatment effect on OS remained insignificant based on the multivariate analysis (hazard ratio 1.16; p = 0.0682). When OS was analyzed by histology subgroup there was also no significant difference between the two arms for patients with glioblastoma multiforme (MST: 10.3 vs. 11.2 months; p = 0.34), anaplastic astrocytoma (MST: 69.8 vs. 50.0 months; p = 0.91) or anaplastic oligodendroglioma (MST: 92.1 vs. 66.5 months; p = 0.33). Though this trial provided many invaluable secondary analyses, there was no trend or indication of a benefit to HFX radiation to 72.0 Gy in any subset of malignant glioma patients.
引用
- Ali AN, Zhang P, Yung WKA, et al. NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol. 2018. PMID: 29404979. doi:10.1007/s11060-017-2558-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。